Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled 

"Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins on Wednesday, June 10, 2026, from 12:00–1:00 PM EDT (9:00–10:00 AM PDT).

Interested participants are invited to register and secure their spot in this exclusive session.

The webinar will provide an in-depth review of the latest clinical data from the Company's ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

Featured Speakers:

Dr. Anahita Bassir Nia, MD- Assistant Professor of Psychiatry, Yale School of Medicine. Leads clinical trials on psychedelics and novel compounds for AUD, depression, and PTSD.

Dr. Jennifer Ellis, Ph.D.- Assistant Professor and licensed clinical psychologist, Johns Hopkins Medicine. Principal investigator at the Johns Hopkins trial site, focused on novel therapeutics for substance use disorders.

Dr. Adi Zuloff-Shani, Ph.D.- CEO of Clearmind Medicine, will provide a clinical development and corporate update.

Host & Moderator: The webinar will be moderated by Shannon Smadella, MBA, Co-Executive Director of World Psychedelics Day, former board member of MAPS Canada, and Special Advisor to Clearmind Medicine.

The event is open to the public and will include a live Q&A session. Registration is available via Eventbrite.